Molecular basis of variability in EGFR-targeted therapy response in non-small cell lung cancer
10.3969/j.issn.1006-5725.2024.15.021
- VernacularTitle:非小细胞肺癌表皮生长因子受体靶向治疗的研究进展
- Author:
Yut-Ing LI
1
;
Qilu YAN
;
Qibin SONG
Author Information
1. 武汉大学人民医院肿瘤中心(武汉 430060)
- Keywords:
non-small cell lung cancer;
EGFR mutations;
targeted therapy;
molecular structure
- From:
The Journal of Practical Medicine
2024;40(15):2166-2171
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most fatal malignant tumor worldwide,with non-small cell lung cancer(NSCLC)being the predominant pathological subtype.The development of NSCLC is driven by mutations in the epidermal growth factor receptor(EGFR),and EGFR tyrosine kinase inhibitors(EGFR-TKIs)are employed as targeted therapies for first-line treatment of advanced NSCLC patients harboring EGFR mutations.However,varia-tions in molecular structures,concurrent mutations,and mechanisms of therapeutic resistance contribute to prog-nostic disparities among different EGFR subgroups.This review primarily summarizes the molecular structural basis and differential treatment responses associated with distinct types of EGFR mutations in NSCLC.
